Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 12 member 2 (SLC12A2), commonly known as Na-K-Cl cotransporter 1 (NKCC1), is an electroneutral transmembrane symporter that mediates the coupled transport of sodium, potassium, and chloride ions across the plasma membrane. It plays a fundamental role in regulating cell volume, maintaining intracellular chloride homeostasis, and driving transepithelial fluid secretion in secretory epithelia. In the developing central nervous system, NKCC1 is highly expressed in immature neurons, where its chloride-importing activity establishes a high intracellular chloride concentration, rendering GABAergic signaling depolarizing and excitatory. As the brain matures, a developmental switch occurs where KCC2 expression increases and NKCC1 decreases, shifting GABA to its classical inhibitory role.\n\nDysregulation or mutations in SLC12A2 are implicated in several human pathologies. Loss-of-function mutations cause neurodevelopmental disorders, hypotonia, and sensorineural hearing loss (such as Delpire-McNeill syndrome and DFNA78/79) due to disrupted endolymph production in the inner ear and impaired neuronal development. Conversely, upregulated NKCC1 activity is associated with neonatal seizures, epilepsy, schizophrenia, autism spectrum disorders, and cerebral edema following traumatic brain injury. In oncology, NKCC1 is overexpressed in glioblastoma, colorectal cancer, and other malignancies, where it facilitates cell migration, invasion, and metastasis by modulating cell volume and cytoskeletal dynamics. NKCC1 is the primary target of loop diuretics such as bumetanide and furosemide, which inhibit its cotransport activity by binding to the extracellular translocation site. However, therapeutic targeting of NKCC1 in the brain is challenged by poor blood-brain barrier penetration of existing drugs and systemic side effects, including profound diuresis and ototoxicity.
Inhibition of Na-K-Cl cotransport
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 12 member 2 (NKCC1).